



ISSN Print 2231 – 3648
 Online 2231 – 3656

Available Online at: www.ijpir.com

International Journal of Pharmacy and Industrial Research

Enhancement of oral bioavailability of sumatriptan mucoadhesive buccal tablets using various polymers

Nellutla Sandeepthi^{1*}, Srikanth Choudary Pallothu²

¹Associate Professor, Omega College of Pharmacy, Edulabad, Hyderabad, Ghatkesar, Telangana 501301.

²Associate Professor, Omega College of Pharmacy, Edulabad, Hyderabad, Ghatkesar, Telangana 501301.

ABSTRACT

Buccal region of the oral cavity is an attractive target for administration of the drug of choice. Buccal delivery involves the administration of the desired drug through the buccal mucosal membrane lining of the oral cavity. By the way improvisation of oral bioavailability of low bioavailability drugs can be achieved. Hence, in the present work mucoadhesive buccal tablets of Sumatriptan succinate will be prepared using different natural and synthetic polymers to improve the oral bioavailability. Buccal sustained release matrix tablets of Sumatriptan succinate containing different grades of HPMC were subjected to *in vitro* drug release studies in pH 6.8 Buffer for 8 hours. The cumulative percent of drug released from the formulations F7 and F8 at the end of 8 hrs is 93.45 ± 0.52 , 97.04 ± 0.7 respectively. Thus the formulation of aforementioned depicts that the bioavailability of the drug has been notably increased.

Keywords: Oral bioavailability, buccal tablets, Sumatriptan succinate and polymers.

INTRODUCTION

The popularity of oral route is attributed to patient acceptance, ease of administration accurate dosing, cost effective manufacturing methods, and generally improve the shelf life of the product. In recent years, the interest in novel routes of drug administration occurs from their ability to enhance the bioavailability of drugs.

Drugs can be absorbed from the oral cavity through the oral mucosa either sublingually or buccally [1-5]. Absorption of therapeutic agents from these routes overcomes premature drug degradation within the gastrointestinal tract as well as active drug loss due to first-pass hepatic metabolism that may be associated with oral route of administration. Difficulties associated with the

Author for Correspondence:

Nellutla Sandeepthi

Associate Professor,

Omega College of Pharmacy, Edulabad, Hyderabad, Ghatkesar, Telangana 501301.

Email: sandeepthi06@gmail.com

parental delivery and poor oral bioavailability provided the impetus for exploring alternative routes for the delivery of such drugs [6-10].

Buccal dosage forms can also be classified as either a reservoir or matrix type. In the reservoir type, an excessive amount of the drug is present in the reservoir surrounded by a polymeric membrane, which controls the drug's release rate. In the matrix type systems, the drug is uniformly dispersed in the polymer matrix, and drug release is controlled by diffusion through the polymer network. Bioadhesive formulations use polymers as the adhesive component. These formulations are often water soluble and when in a dry form attract water from the biological surface and this water transfer leads to a strong interaction [11-15].

MATERIALS AND METHODS

All the chemicals and reagents used in the research work are obtained from the reputed vendors. Sumatriptan succinate is obtained as a gift sample from Dr. Reddys Laboratories Ltd., All others excipients are obtained from SD fine Chem [16-20].

Preformulation studies

Preformulation testing is the first step in the rational development of dosage forms of a drug substance. It can be defined as an investigation of physical and chemical properties of a drug substance alone and when combined with excipients. Main objective of performing preformulation studies to generate useful information to prepare the formulation in developing stable and bioavailable dosage forms.

Drug and excipient compatibility studies

A successful formulation of a stable and effective solid dosage form depends on careful selection of excipients that are added to facilitate administration, promote the consistent release and bioavailability of the drug and protect it from degradation. If the excipients are new and not been used in formulation containing the active substance, the compatibility studies are of paramount importance.

Sumatriptan succinate stock solution

Standard stock solution was prepared by dissolving 10 mg of Sumatriptan succinate in 100 mL organic solvent of methanol to get concentration of 100 µg/mL solution [21-24].

Table 1. Master Formula (F1 to F6)

Ingredients	F1	F2	F3	F4	F5	F6
Drug(mg)	25	25	25	25	25	25
SLS(%)	0.05	0.05	0.05	0.05	0.1	0.2
Talc	0.7	0.7	0.7	0.7	0.65	0.55
Mg stearate	0.35	0.35	0.35	0.35	0.35	0.35
Crbopol 934P	12.5	25	37.5	12.5	12.5	12.5
HPMC K4M	-	-	-	12.5	12.5	12.5
HPMC K15M	-	-	-	-	-	-
HPMC K100M	-	-	-	-	-	-
MCC	31.4	18.9	6.4	18.9	18.9	18.9
Total weight(mg)	70	70	70	70	70	70

Table 2. Master Formula (F7 to F12)

Ingredients	F7	F8	F9	F10	F11	F12
Drug	25	25	25	25	25	25
SLS (%)	0.05	0.1	0.2	0.05	0.1	0.2
Talc	0.7	0.65	0.55	0.7	0.65	0.55
Mg stearate	0.35	0.35	0.35	0.35	0.35	0.35
Carbopol 934P	12.5	12.5	12.5	12.5	12.5	12.5
HPMC K4M	-	-	-	-	-	-
HPMC K15M	12.5	12.5	12.5	-	-	-
HPMC K100M	-	-	-	12.5	12.5	12.5
MCC	18.9	18.9	18.9	18.9	18.9	18.9
Total weight(mg)	70	70	70	70	70	70

FTIR Compatibility Studies

FTIR spectra of pure drug and formulation with other ingredients were recorded. The FTIR Spectra of pure Sumatriptan succinate drug and polymer was compared with the FT-IR spectrum of drug and polymer, physical mixture (Sumatriptan succinate, HPMC K15 and

Carbopol) in the figures, respectively. The characteristic functional groups of the pure Sumatriptan succinate showed the peaks at the following wave number region. NH stretching (Amine) at 3369.04 cm^{-1} , Ketone (C=O) stretching at 1707.11 cm^{-1} , C-N at 1392.79 cm^{-1} , S=O at 1079.81 cm^{-1} .

Table 3. FTIR peaks of drug and excipients

IR Spectra	Peak of functional groups [Wave number (cm^{-1})]					
	NH	CH	C=O	C-N	S=O	C=C
Sumatriptan succinate	3369.04	2970.48	1707.11	1392.79	1079.81	1542.65
Glimepride+ Carbopol 934P	3369.06	2931.30	1724.28	1393.69	1080.01	1542.68
Sumatriptan succinate+ HPMC K15M	3369.09	2933.21	1708.32	1392.79	1079.51	1542.49
Optimized formulation	3369.06	2930.38	1708.32	1392.79	1079.5	1542.40




Figure 8. FTIR spectrum of pure drug.




Figure 9. FTIR spectrum of drug and HPMC K15M




Figure 10. FTIR spectrum of Drug and Carbopol




Figure 11. FTIR spectrum of final formulation.

Standard graph in phosphate buffer pH 6.8
(λ_{\max} 249nm)

Standard graph of Sumatriptan succinate was plotted as per the procedure in experimental

method. The standard graph of Sumatriptan succinate showed good linearity with R^2 of 0.996, which indicates that it obeys “Beer- Lamberts” law.

Table 19. Standard graph of Sumatriptan succinate in phosphate buffer pH 6.8

Concentration ($\mu\text{g/mL}$)	Absorbance
0	0
8	0.301
10	0.392
12	0.483
14	0.572
16	0.668
18	0.741




Figure.13 Standard graph of Sumatriptan succinate in phosphate buffer pH 6.8

Pre-compression parameters.

The pre-compression parameters like bulk density, angle of repose, tapped density, Carr's index and Hausner ratio have been performed.

Table 20. Pre-compression parameters.

S. NO	Angle of repose	Bulk density (gm/cm ³)	Tapped density (gm/cm ³)	Hausner's ratio	Carr's Index (%)
F1	21.04±0.57	0.22±0.02	0.26±0.12	1.19± 0.06	16.34±0.02
F2	23.08±0.59	0.22±0.08	0.24±0.06	1.06±0.64	9.46±0.15
F3	21.36±0.38	0.23±0.07	0.25±0.015	1.07±0.34	6.08±0.45
F4	25.32±0.61	0.23±0.02	0.24±0.06	1.05±0.45	5.33±0.09
F5	24.45±0.12	0.23±0.07	0.27±0.03	1.16±0.12	13.82±0.52
F6	22.79±0.21	0.27±0.01	0.31±0.08	1.12±0.16	11.36±0.30
F7	23.92±0.69	0.26±0.01	0.29±0.12	1.10±0.78	9.62±0.10
F8	22.47±0.09	0.30±0.07	0.33±0.07	1.09±0.04	8.85±0.09
F9	25.69±0.71	0.35±0.65	0.38±0.14	1.21±0.06	17.39±0.03
F10	26.10±0.65	0.33±0.06	0.41±1.31	1.24±0.034	19.68±0.20
F11	21.38±0.08	0.29±0.09	0.34±0.09	1.18±0.08	15.31±0.09
F12	25.53±0.59	0.28±0.08	0.32±0.02	1.17±0.06	14.82±0.03

Physicochemical characterization of buccal tablets

The shape and size of the prepared tablets were found to be within the limit. The average

weight was found to be within the prescribed limit. The hardness of the tablets was found to be in the range of 3.0±0.21 to 4.5±0.64 (kg/cm²).

Table 21. Physico-chemical parameters of Sumatriptan succinate buccal tablets

Formulation Code	Weight variation (mg)	Thickness (mm)	Hardness (kg/cm ²)	Friability (%)	Assay (%)
F1	69.28 ± 0.61	1.85 ± 0.03	4.5±0.25	0.55±0.07	98.05 ± 0.84
F2	70.04 ± 0.80	1.76 ± 0.02	4.0±0.30	0.63±0.13	99.73 ± 0.56
F3	70.38 ± 0.71	1.94 ± 0.03	3.0±0.45	0.66±0.08	97.15 ± 1.2
F4	71.45 ± 0.64	1.95 ± 0.02	3.5±0.20	0.58±0.19	99.77 ± 0.60
F5	69.91 ± 1.01	1.97 ± 0.02	3.5±0.28	0.64±0.16	101.96± 0.54
F6	69.98 ± 0.82	2.01 ± 0.01	3.5±0.40	0.47±0.17	99.81 ± 0.96
F7	70.38 ± 0.80	2.00 ± 0.02	3.0±0.21	0.66±1.2	97.86 ± 1.6
F8	68.04 ± 0.71	1.94 ± 0.03	4.5±0.64	0.65±0.65	100.81± 1.21
F9	69.94 ± 0.75	2.05 ± 0.02	4.0±0.29	0.43±0.09	99.35 ± 0.85
F10	68.68±1.2	2.06 ± 0.01	4.5±0.40	0.61±0.48	100.65± 0.96
F11	70.45 ± 0.64	2.04 ± 0.02	3.5±0.14	0.66±0.12	99.83 ± 0.52
F12	70.71 ± 1.01	2.55 ± 0.02	3.5±0.15	0.58±0.78	98.90 ± 0.75

Each value represents the mean ±SD (n =3)

***In vitro* drug release studies**

In vitro drug release studies were conducted in phosphate buffer pH 6.8 and the studies revealed

that the release of Sumatriptan succinate from different formulations.

Time (hr)	F1	F2	F3	F4	F5	F6
0	0	0	0	0	0	0
0.5	47.9±0.8	37.8±0.65	35.77±1.1	45.7±1.1	41.06±2.5	37.9±1.5
1	61.07±0.6	48.06±2.1	47.34±0.75	66.1±1.5	55.68±0.9	51.68±0.9
2	90.9±1.32	81.43±1.45	71.5±2.6	74±2.3	73.3±1.6	64.7±0.5
3	-	94.72±0.96	88.92±0.45	91.6±1.7	84.8±1	81.73±1.5
4	-	-	97.19±0.96	96.65±0.9	92.6±0.7	88.96±0.3
5	-	-	-	-	98.04±0.9	91.09±1
6	-	-	-	-	-	98.45±2.1
7	-	-	-	-	-	-
8	-	-	-	-	-	-

Table

Time (hr)	F7	F8	F9	F10	F11	F12
0	0	0	0	0	0	0
0.5	21.52±0.5	18.76±0.45	34.6±0.29	3.2±0.5	3.0±0.5	2.6±0.5
1	35.84±0.5	34.06±0.93	57.8±0.7	8.2±1	3.8±1	4.2±0.7
2	55.23±0.72	46.89±0.25	72.12±2.5	18.8±1.5	8.8±1.5	9.9±1.6
3	79.05±0.23	52.43±1.2	85.03±1.9	29.6±0.9	16.6±0.9	18.5±1.8
4	83.03±0.15	61.05±1.8	91.67±2.1	45.7±0.7	24.2±0.7	32.1±2.1
5	86.41±1.6	70.65±0.9	94.7±1.7	54.9±1.7	31.3±1.5	42±0.5
6	88.63±0.9	88.91±0.16	99.27±1.3	66.1±1.9	42.0±0.95	54.3±1.2
7	91.06±1.6	93.46±0.8	-	74.0±0.9	51.9±2.1	62.7±1.6
8	93.45±0.52	97.04±0.7	-	90.3±1.8	63.7±1.6	76.1±2.5

***In vitro* release of Sumatriptan succinate from Carbopol 934.**

Formulations F1, F2 and F3 could not retarded drug release. In the formulation F1, F2, F3 only single polymer is used.




Figure14. *In vitro* release of Sumatriptan succinate from HPMC K4M.

***In vitro* release of Sumatriptan succinate from HPMC K4M and Carbopol**

Carbopol 934P were subjected to *in vitro* drug release studies in pH 6.8 Buffer for 8 hours.

Buccal sustained release matrix tablets of Sumatriptan succinate containing HPMC K4 and




Figure 15. *In vitro* release of Sumatriptan succinate from HPMC K4M and Carbopol 934P




Figure 16. *In vitro* relies of Glimipiride form HPMC K15M and carbopol934P

***In Vitro* Release of Sumatriptan succinate from HPMC K100M and Carbopol**

Formulations of Sumatriptan succinate containing HPMC K100M and Carbopol (F10,

F11 and F12) showed the drug release of 90.3 ± 1.8 , 63.7 ± 1.64 and 76.1 ± 2.5 at the end of 8th hr respectively.




Figure 17. *In Vitro* Release of Sumatriptan succinate from HPMC K100M and Carbopol

Swelling Studies of buccal tablets

Appropriate swelling property of a buccal device is essential for uniform and prolonged release of drug and proper bioadhesion.

Table 24. Swelling studies of buccal tablets

Time (hrs)	% Swelling index
	F8
0	0
0.5	3.19 ± 0.39
1	6.50 ± 0.11
2	9.28 ± 0.28
3	12.15 ± 0.31
4	13.44 ± 0.32
5	15.35 ± 0.71
6	17.64 ± 0.19
7	19.35 ± 0.30
8	20.82 ± 0.63

Each value represents the mean ± SD (n=3)




Figure 18. Swelling Studies of Sumatriptan succinate selected buccal tablets

Ex vivo permeation studies of Sumatriptan succinate buccal tablets

Based on the *in vitro* drug release studies, F7, F8 and F9 selected for the *ex vivo* permeation study. The flux, permeation coefficient and cumulative percent drug permeated from formulations F7, F8 and F9 were found to be

0.6029 mg.hrs⁻¹cm⁻², 0.0753cm/h and 58.4% respectively. Due to the low permeability of drug from the formulation, permeation enhancer (sodium taurocholate) was added in the concentration of 10 mM to the optimized formulation to increase the permeability.

Table Drug release of Sumatriptan succinate *Ex vivo* permeated buccal tablets

Time (hrs)	Drug solution	F7	F8	F9	Formulation without enhancer
0	0	0	0	0	0
0.5	12.74±0.13	11.30±0.19	14.53±0.05	16.23±0.05	10.53±0.91
1	28.23±0.17	23.64±0.34	29.43±0.14	31.33±0.14	19.97±0.56
2	30.24±0.21	37.74±0.85	36.71±0.37	37.47±0.37	34.68±0.85
3	38.62±0.15	47.61±0.45	49.77±2.13	53.65±2.13	43.26±1.02
4	46.72±0.16	54.22±2.09	55.98±1.33	55.28±1.33	51.70±2.49
5	57.81±0.23	61.43±1.06	57.32±1.19	58.24±1.19	56.89±1.90
6	68.54±0.53	67.31±0.72	66.78±1.02	64.81±1.02	62.40±1.30
7	78.13±0.89	78.77±1.23	77.99±2.19	76.69±2.19	71.13±0.72
8	87.29±1.32	81.33±1.89	85.28±3.43	83.28±3.43	78.34±1.36
FLUX	110.452	189.87 μg/hr	194.15 μg/hr	193.45 μg/hr	168.96 μg/hr cm ²
	μg.hr ⁻¹ cm ⁻²	cm ²	cm ²	cm ²	

Each value represents the mean ± SD (n=3)




Figure19. Drug release of Sumatriptan succinate *Ex vivo* permeated buccal tablets.

The *ex vivo* permeation studies of selected formulations were conducted, the values of flux and permeability coefficients were found to be $189.87\mu\text{g hr}^{-1}\text{ cm}^2$, $193.45\mu\text{g hr}^{-1}\text{ cm}^2$, $194.15\mu\text{g hr}^{-1}\text{ cm}^2$ and 0.158 cm/h , 0.126 cm/h and 0.197 cm/h .

oral bioavailability with various synthetic and natural polymers has given, a considerable attention and significance towards the results. The formulation F8 has shown remarkable results in the aspect of post and pre compressional parameters with the drug release of more than 85 % in 8 hours, it is quite satisfactory. Hence it

CONCLUSION

Current research revealing of the fabrication of Sumatriptan succinate for the betterment of the

REFERENCES

- [1]. Vyas SP, Khar RK. Controlled drug delivery-concepts and advances. New Delhi: Vallabh Prakashan; 1, 2002.
- [2]. Shojaei HA. Buccal mucosa as a route for systemic drug delivery: A Review. J Pharm Sci. 1(1), 1998, 15-30.
- [3]. David Haris, Robinson JR. Buccal drug delivery via the mucous membranes of the oral cavity. J Pharm Sci. 81(1), 1992, 1-9.
- [4]. Tor-Tora Gorahowski. Principles of anatomy and physiology. Edited by Gerard J. Tor- Tora and Sandro Reynolds Gorahowski: Harpet Collins College Publishers; 1992, 770-774.
- [5]. Ross & Wilson. Anatomy & physiology in health and illness. 9th ed. Edited by Anne Waugh and Allison Goraw: Churchill LivingstoneEdinburgh Publishers; 2001, 289-293.
- [6]. Chatterjee CC. Human physiology. 10th ed. Calcutta: Medical Allied Agency; 1985, 427-434.
- [7]. Pramod KTM, Shivakumar HG and Desai KG. Oral transmucosal drug delivery systems. Indian Drugs. 41(2), 2004, 63-67.
- [8]. Chen YS, Squier CA. The ultra structure of the oral epithelium. In: J. Meyer, CA. Squier, SJ. Gerson (eds.), The structure and function of oral mucosa, Pergamon Press, Oxford. 1984, 7-30.
- [9]. Swarbrick James. Bioadhesive drug delivery systems. 1st ed. New York: Marcel Dekker Inc; 1999, 541-562.
- [10]. Hayward AF. Membrane-coating granules. Int Rev Cyt. 59, 1979, 97-127.
- [11]. Squier CA, Eady RA, Hopps RM. The permeability of epidermis lacking normal membrane-coating granules: an ultra structural tracer study of Kyrle-Flegel disease. J Invest Dermatol. 70, 1978, 361-364.
- [12]. Robinson JR, Yang X. Absorption enhancers. In: J. Swarbrick, JC. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker Inc; 18, 2001, 1-27.

- [13]. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P. Factors and strategies for improving buccal absorption of peptides. *Eur J Pharm Biopharm.* 51, 2001, 93-109.
- [14]. Walker GF, N. Langoth, A. Bernkop- Schnürch. Peptidase activity on the surface of the porcine buccal mucosa. *Int J Pharm.* 233, 2002, 141-147.
- [15]. Miller SC, Donovan MD. Effect of poloxamer 407 gel on the meiotic activity of pilocarpine nitrate in rabbits. *Int J Pharm.* 12, 1982, 147-152.
- [16]. Wong CF, Yuen KH, Peh KK. Formulation and evaluation of controlled release Eudragit buccal patches. *Int J Pharm.* 178, 1999, 11-22.
- [17]. Kumar S, Haglund BO, Himmelstein KJ. In situ- forming gels for ophthalmic drug delivery. *J Ocul Pharmacol.* 10, 1994, 47-56.
- [18]. Gurny R, Ryser JE, Tabatabay C, Martenet M, Edman P, Camber O. Precorneal residence time in humans of sodium hyaluronate as measured by gamma scintigraphy. *Graefe Arch Clin Exp Ophthalmol* 228, 1990, 510-512.
- [19]. Meseguer G, Gurny R, Buri P. Gamma scintigraphic evaluation of precorneal clearance in human volunteers and in rabbits. *Eur J Drug Meta Pharma.* 18, 1993, 190-194.
- [20]. Martin L, Wilson CG, Koosha F, Uchegbu IF. Sustained buccal delivery of the hydrophobic drug denbufylline using physically cross- linked palmitoyl glycol chitosan hydrogels. *Eur J Pharm Biopharm.* 55, 2003, 35-45.
- [21]. Rudnic EM, Schwartz JD. Oral solid dosage forms. In: Gennaro AR (editor). *Remington: the science and practice of pharmacy.* 20th ed. Lippincott Williams & Wilkins, Baltimore; 2000, 858-859.
- [22]. Hannan Butchelov. Novel bioadhesive formulation in drug delivery an oral presentation at the British pharmaceutical conference. *The drug delivery companies pharmaventures Ltd.* 2004, 22-26.
- [23]. Dkinci G, Çapan Y, Senel S, Alaaddinogu E, Dalkara T, Hincal AA. In vitro/in vivo studies on a buccal bioadhesive tablet formulation of carbamazepine. *Pharmazie.* 55, 2000, 762-765.
- [24]. Giunchedi P, Juliano C, Gavini E, Cossu M, Sorrenti M. Formulation and in vivo evaluation of chlorhexidine buccal tablets prepared using drug-loaded chitosan microspheres. *Eur J Pharm Biopharm.* 53, 2002, 233-239.